Targeting MAKAPβ Expression As a Therapeutic Approach for Ischemic Cardiomyopathy

Overview

Journal Gene Ther

Date 2022 Feb 1

PMID 35102273

Authors

Eliana C Martinez

Jinliang Li

Jennifer Arthur Ataam

Kristin Tokarski

Hrishikesh Thakur

Ioannis Karakikes

Kimberly Dodge-Kafka

Michael S Kapiloff

Affiliations

Soon will be listed here.

Abstract

Ischemic cardiomyopathy is a leading cause of death and an unmet clinical need. Adeno-associated virus (AAV) gene-based therapies hold great promise for treating and preventing heart failure. Previously we showed that muscle A-kinase Anchoring Protein β (mAKAPβ, AKAP6β), a scaffold protein that organizes perinuclear signalosomes in the cardiomyocyte, is a critical regulator of pathological cardiac hypertrophy. Here, we show that inhibition of mAKAPβ expression in stressed adult cardiomyocytes in vitro was cardioprotective, while conditional cardiomyocyte-specific mAKAP gene deletion in mice prevented pathological cardiac remodeling due to myocardial infarction. We developed a new self-complementary serotype 9 AAV gene therapy vector expressing a short hairpin RNA for mAKAPβ under the control of a cardiomyocyte-specific promoter (AAV9sc.shmAKAP). This vector efficiently downregulated mAKAPβ expression in the mouse heart in vivo. Expression of the shRNA also inhibited mAKAPβ expression in human induced cardiomyocytes in vitro. Following myocardial infarction, systemic administration of AAV9sc.shmAKAP prevented the development of pathological cardiac remodeling and heart failure, providing long-term restoration of left ventricular ejection fraction. Our findings provide proof-of-concept for mAKAPβ as a therapeutic target for ischemic cardiomyopathy and support the development of a translational pipeline for AAV9sc.shmAKAP for the treatment of heart failure.

Citing Articles

NE-MTOC Formation in Skeletal Muscle Is Mbnl2-Dependent and Occurs in a Sequential and Gradual Manner.

Das P, Becker R, Vergarajauregui S, Engel F Cells. 2025; 14(4).

PMID: 39996710 PMC: 11853192. DOI: 10.3390/cells14040237.

Protein phosphatase 2A anchoring disruptor gene therapy for familial dilated cardiomyopathy.

Li X, Li J, Samuelsson A, Thakur H, Kapiloff M Mol Ther Methods Clin Dev. 2024; 32(2):101233.

PMID: 38572067 PMC: 10988123. DOI: 10.1016/j.omtm.2024.101233.

AAV-mediated gene therapy: Advancing cardiovascular disease treatment.

Zhang H, Zhan Q, Huang B, Wang Y, Wang X Front Cardiovasc Med. 2022; 9:952755.

PMID: 36061546 PMC: 9437345. DOI: 10.3389/fcvm.2022.952755.

A perinuclear calcium compartment regulates cardiac myocyte hypertrophy.

Turcotte M, Thakur H, Kapiloff M, Dodge-Kafka K J Mol Cell Cardiol. 2022; 172:26-40.

PMID: 35952391 PMC: 9727780. DOI: 10.1016/j.yjmcc.2022.07.007.

Distribution of cardiomyocyte-selective adeno-associated virus serotype 9 vectors in swine following intracoronary and intravenous infusion.

Li J, Kelly S, Ivey J, Thorne P, Yamada K, Aikawa T Physiol Genomics. 2022; 54(7):261-272.

PMID: 35648460 PMC: 9236866. DOI: 10.1152/physiolgenomics.00032.2022.

References

Sam F, Sawyer D, Chang D, Eberli F, Ngoy S, Jain M . Progressive left ventricular remodeling and apoptosis late after myocardial infarction in mouse heart. Am J Physiol Heart Circ Physiol. 2000; 279(1):H422-8. DOI: 10.1152/ajpheart.2000.279.1.H422. View

Pare G, Bauman A, McHenry M, Michel J, Dodge-Kafka K, Kapiloff M . The mAKAP complex participates in the induction of cardiac myocyte hypertrophy by adrenergic receptor signaling. J Cell Sci. 2005; 118(Pt 23):5637-46. DOI: 10.1242/jcs.02675. View

Kieserman J, Myers V, Dubey P, Cheung J, Feldman A . Current Landscape of Heart Failure Gene Therapy. J Am Heart Assoc. 2019; 8(10):e012239. PMC: 6585330. DOI: 10.1161/JAHA.119.012239. View

Negro A, Dodge-Kafka K, Kapiloff M . Signalosomes as Therapeutic Targets. Prog Pediatr Cardiol. 2009; 25(1):51-56. PMC: 2390861. DOI: 10.1016/j.ppedcard.2007.11.012. View

Dodge-Kafka K, Gildart M, Li J, Thakur H, Kapiloff M . Bidirectional regulation of HDAC5 by mAKAPβ signalosomes in cardiac myocytes. J Mol Cell Cardiol. 2018; 118:13-25. PMC: 5940533. DOI: 10.1016/j.yjmcc.2018.03.001. View

Zaccolo M, Zerio A, Lobo M . Subcellular Organization of the cAMP Signaling Pathway. Pharmacol Rev. 2020; 73(1):278-309. PMC: 7770493. DOI: 10.1124/pharmrev.120.000086. View

Li J, Tan Y, Passariello C, Martinez E, Kritzer M, Li X . Signalosome-Regulated Serum Response Factor Phosphorylation Determining Myocyte Growth in Width Versus Length as a Therapeutic Target for Heart Failure. Circulation. 2020; 142(22):2138-2154. PMC: 7704863. DOI: 10.1161/CIRCULATIONAHA.119.044805. View

Sutton M, Sharpe N . Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000; 101(25):2981-8. DOI: 10.1161/01.cir.101.25.2981. View

Silva J, Li M, Chang K, Ge W, Golding M, Rickles R . Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet. 2005; 37(11):1281-8. DOI: 10.1038/ng1650. View

10.

Omar M, Scott J . AKAP Signaling Islands: Venues for Precision Pharmacology. Trends Pharmacol Sci. 2020; 41(12):933-946. PMC: 7890593. DOI: 10.1016/j.tips.2020.09.007. View

11.

Prasad K, Xu Y, Yang Z, Acton S, French B . Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution. Gene Ther. 2010; 18(1):43-52. PMC: 2988989. DOI: 10.1038/gt.2010.105. View

12.

Konkalmatt P, Wang F, Piras B, Xu Y, OConnor D, Beyers R . Adeno-associated virus serotype 9 administered systemically after reperfusion preferentially targets cardiomyocytes in the infarct border zone with pharmacodynamics suitable for the attenuation of left ventricular remodeling. J Gene Med. 2012; 14(9-10):609-20. PMC: 3729029. DOI: 10.1002/jgm.2673. View

13.

Zhang L, Malik S, Pang J, Wang H, Park K, Yule D . Phospholipase Cε hydrolyzes perinuclear phosphatidylinositol 4-phosphate to regulate cardiac hypertrophy. Cell. 2013; 153(1):216-27. PMC: 3615249. DOI: 10.1016/j.cell.2013.02.047. View

14.

Pare G, Easlick J, Mislow J, McNally E, Kapiloff M . Nesprin-1alpha contributes to the targeting of mAKAP to the cardiac myocyte nuclear envelope. Exp Cell Res. 2005; 303(2):388-99. DOI: 10.1016/j.yexcr.2004.10.009. View

15.

Dodge-Kafka K, Bauman A, Mayer N, Henson E, Heredia L, Ahn J . cAMP-stimulated protein phosphatase 2A activity associated with muscle A kinase-anchoring protein (mAKAP) signaling complexes inhibits the phosphorylation and activity of the cAMP-specific phosphodiesterase PDE4D3. J Biol Chem. 2010; 285(15):11078-86. PMC: 2856983. DOI: 10.1074/jbc.M109.034868. View

16.

Kritzer M, Li J, Passariello C, Gayanilo M, Thakur H, Dayan J . The scaffold protein muscle A-kinase anchoring protein β orchestrates cardiac myocyte hypertrophic signaling required for the development of heart failure. Circ Heart Fail. 2014; 7(4):663-72. PMC: 4277867. DOI: 10.1161/CIRCHEARTFAILURE.114.001266. View

17.

Feyen D, Perea-Gil I, Maas R, Harakalova M, Gavidia A, Arthur Ataam J . Unfolded Protein Response as a Compensatory Mechanism and Potential Therapeutic Target in PLN R14del Cardiomyopathy. Circulation. 2021; 144(5):382-392. PMC: 8667423. DOI: 10.1161/CIRCULATIONAHA.120.049844. View

18.

Sohal D, Nghiem M, Crackower M, Witt S, Kimball T, Tymitz K . Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. Circ Res. 2001; 89(1):20-5. DOI: 10.1161/hh1301.092687. View

19.

Li J, Negro A, Lopez J, Bauman A, Henson E, Dodge-Kafka K . The mAKAPbeta scaffold regulates cardiac myocyte hypertrophy via recruitment of activated calcineurin. J Mol Cell Cardiol. 2009; 48(2):387-94. PMC: 2813376. DOI: 10.1016/j.yjmcc.2009.10.023. View

20.

Nakamura M, Sadoshima J . Mechanisms of physiological and pathological cardiac hypertrophy. Nat Rev Cardiol. 2018; 15(7):387-407. DOI: 10.1038/s41569-018-0007-y. View